艾瑞昔布联合唑来膦酸治疗恶性肿瘤骨转移疼痛的疗效及对血清ET-1、NPY、PGE_(2)水平的影响  

Efficacy of Imrecoxib Combined with Zoledronic Acid in the Treatment of Bone Metastasis Pain of Malignant Tumors and Its Influence on Serum ET-1,NPY and PGE_(2) Levels

作　　者：郭建阔 李卫华 王仲锋 GUO Jian-kuo;LI Wei-hua;WANG Zhong-feng(Department of Orthopedics,Huaihe Hospital of Henan University,Kaifeng 475000,China)

机构地区：[1]河南大学淮河医院骨科,开封475000

出　　处：《中国合理用药探索》2022年第9期83-88,共6页Chinese Journal of Rational Drug Use

基　　金：河南省医学科技攻关计划项目(2018020335);河南省医学科技攻关计划项目(201404025)。

摘　　要：目的:探讨艾瑞昔布联合唑来膦酸治疗对恶性肿瘤骨转移疼痛患者的疗效和安全性。方法:选取2018年3月~2021年3月本院收治的恶性肿瘤骨转移疼痛患者90例作为研究对象,采用随机数字表法分为对照组和观察组,每组45例。两组均口服给予羟考酮缓释片,此外,对照组给予唑来膦酸治疗,观察组给予艾瑞昔布联合唑来膦酸治疗,两组均以1个月为1个疗程,连续治疗3个月。于治疗前后采用焦虑自评量表(SAS)、抑郁自评量表(SDS)评分以及癌症患者生活质量量表(QLQ-C30)进行评分;对血清内皮素-1(ET-1)、神经肽Y(NPY)、前列腺素E_(2)(PGE_(2))进行测定;比较两组患者镇痛疗效;观察两组患者不良反应发生情况。结果:治疗后,观察组SAS和SDS评分低于对照组(P<0.05),QLQ-C30评分高于对照组(P<0.05);观察组血清ET-1、NPY和PGE_(2)水平低于对照组(P<0.05)。观察组镇痛总有效率(93.33%)高于对照组(75.56%)。两组患者不良反应比较无统计学差异(P>0.05)。结论:艾瑞昔布联合唑来膦酸治疗恶性肿瘤骨转移疼痛疗效较好,能够抑制ET-1、NPY和PGE_(2)的释放,促进疼痛缓解,减轻患者负性情绪,提高患者生活质量。Objective:To investigate the efficacy and safety of imrecoxib combined with zoledronic acid in the treatment of bone metastasis pain in malignant tumors.Methods:A total of 90 patients with malignant tumor bone metastasis pain admitted to our hospital from March 2018 to March 2021 were selected and randomly divided into the control group and the observation group,45 cases in each group.Both groups were given oral oxycodone sustained-release tablets,in addition,the control group was treated with zoledronic acid,and the observation group was treated with imrecoxib combined with zoledronic acid.Both groups were treated with 1 month as a course of treatment for 3 months.Self-rating anxiety scale(SAS),self-rating depression scale(SDS)score and quality of life scale for cancer patients(QLQ-C30)score were performed before and after treatment.Serum endothelin-1(ET-1),neuropeptide Y(NPY)and prostaglandin E_(2)(PGE_(2))were measured.The analgesic effect was compared between the two groups.The incidence of adverse reactions were observed in the two groups.Results:After treatment,the scores of SAS and SDS in the observation group were significantly lower than those of the control group(P<0.05),and the QLQ-C30 score was significantly higher than that of the control group(P<0.05).The levels of serum ET-1,NPY and PGE_(2) in the observation group were significantly lower than those in the control group(P<0.05).The total effective rate of analgesia in the observation group(93.33%)was higher than that in the control group(75.56%).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:The efficacy of imrecoxib combined with zoledronic acid in the treatment of bone metastasis pain of malignant tumors is remarkable,which can inhibit the release of ET-1,NPY and PGE_(2),promote pain relief,reduce the negative emotions of patients and improve patients’quality of life.

关 键 词：恶性肿瘤 骨转移 唑来膦酸 艾瑞昔布 内皮素-1 

分 类 号：R739[医药卫生—肿瘤]